StockData
Tilray Brands, Inc. logo

Tilray Brands, Inc. (TLRY) company profile

TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 11/3087% below fair value
$2.35+0.01 (+0.43%)

Close on Nov 17, 2026Market cap $347.30MP/E –Yield –

About Tilray Brands

Medicinal Chemicals & Botanical Products, SIC 2833

Tilray Brands, Inc. is a consumer goods company operating in four segments: Beverage, Cannabis, Distribution, and Wellness. In beverage, it produces, markets, and sells craft beers, craft spirits, ready-to-drink beverages, ciders, and non-alcoholic drinks. Its cannabis segment cultivates, processes, and sells adult-use and medicinal cannabis products, including dried flower, pre-rolls, vapes, and edibles. Through its distribution and wellness businesses, the company distributes pharmaceutical products and manufactures hemp-based foods. Tilray supplies retail consumers, medical patients, doctors, hospitals, pharmacies, and commercial wholesalers.

Headquartered in Leamington and New York, the company operates in Canada, the United States, Europe, Australia, and Latin America. Tilray supplies medical cannabis to patients across more than twenty countries on five continents, with production facilities in Canada, Germany, and Portugal. Its beverage assets include seven production facilities, eighteen brewpubs, and a distillery in the United States, a brewery in Scotland, and thirty-five owned or franchised pubs across the United Kingdom, Ireland, and Australia.

Summary of the business section of Tilray Brands's latest annual report, written by StockData.

Company profile

Company

Legal name
Tilray Brands, Inc.
Founded
2018
Headquarters
New York, NY
Address
445 Park Avenue 10022
Phone
(519) 322-8800
Employees
3,595, May 31, 2026
Industry
Medicinal Chemicals & Botanical Products
Fiscal year ends
May 31
Auditor
PricewaterhouseCoopers LLP, Toronto, Canada

Stock & identifiers

Ticker
TLRY
Exchange
Nasdaq
IPO date
Jul 19, 2018
Shares outstanding
148M, Oct 6, 2026
Public float
$900.00M, Nov 28, 2025
Filer category
Large accelerated filer
Stock splits
1-for-10 reverse, Dec 2, 2025
SEC CIK
1731348
CUSIP
88688T209
ISIN
US88688T2096
FIGI
BBG00L7XTP60
Share class FIGI
BBG00L7XTPY9
LEI
549300Y4V60733TO1478
EIN
82-4310622

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Irwin D. SimonPresident and CEO, Director1,309,031
Mitchell GendelGlobal General Counsel148,644
Denise M. FaltischekChief Strategy Officer199,489
Carl A. MertonChief Financial Officer241,556
Johann Michael HerhaltDirector195,561
Thomas P. LooneyDirector397,520
Renah PersofskyDirector155,357
Steven Michael CohenDirector55,542
David F. ClanachanDirector192,511
David G. HopkinsonDirector43,104

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$22.16M$18.59M$3.43M$3$16
FY2025
Brendan Kennedy
$0$0$1.99M$3$14
FY2025
Irwin Simon
$10.30M-$5.09M$1.99M$3$14
FY2024
Brendan Kennedy
$0$0$2.06M$11$21
FY2024
Irwin Simon
$10.14M$11.15M$2.06M$11$21
FY2023$0$0$2.37M$10$20

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Irwin Simon
President, Chief Executive Officer and Chairman of the Board
$2.06M$950.00K$18.82M$333.22K$22.16M+115%
Carl Merton
Chief Financial Officer
$411.66K$160.00K$2.65M$21.30K$3.24M+99%
Denise Faltischek
Chief Strategy Officer and Head of M&A
$642.74K$130.00K$3.06M$41.13K$3.87M+64%
Mitchell Gendel
Global General Counsel and Corporate Secretary
$599.89K$160.00K$2.73M$32.30K$3.52M+61%
Roger Savell
Chief Administrative Officer
$562.32K$105.00K$2.36M$39.49K$3.07M+72%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 19, 2018
Offer price
$17.00
Securities offered
9,000,000
Gross proceeds
$153.00M
Exchange
Nasdaq
First trading day
Jul 19, 2018
First-day close
$22.39+31.7%
Lock-up ends (est.)
Jan 15, 2019

“See the sections titled “ Management—Controlled Company Exception ” and “ Principal Stockholders .” Per Share Total Initial public offering price $17.00 $153,000,000 Underwriting discount (1) $1.19 $10,710,000 Proceeds, before expenses, to us $15.81 $142,290,000 (1) We refer you to the section titled “ Underwriting ” beginning on page 133 of this prospectus for additional information regarding underwriting compen”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of May 31, 2026, we have approximately 3,595 employees worldwide.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?